Erasca Past Earnings Performance
Past criteria checks 0/6
Erasca's earnings have been declining at an average annual rate of -30.6%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-30.6%
Earnings growth rate
25.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -39.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21
We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Revenue & Expenses BreakdownBeta
How Erasca makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -125 | 38 | 104 |
| 30 Sep 23 | 0 | -231 | 37 | 108 |
| 30 Jun 23 | 0 | -236 | 37 | 111 |
| 31 Mar 23 | 0 | -240 | 35 | 113 |
| 31 Dec 22 | 0 | -243 | 34 | 114 |
| 30 Sep 22 | 0 | -138 | 31 | 107 |
| 30 Jun 22 | 0 | -149 | 29 | 99 |
| 31 Mar 22 | 0 | -141 | 26 | 89 |
| 31 Dec 21 | 0 | -123 | 23 | 74 |
| 30 Sep 21 | 0 | -154 | 19 | 60 |
| 30 Jun 21 | 0 | -119 | 14 | 49 |
| 31 Mar 21 | 0 | -96 | 10 | 37 |
| 31 Dec 20 | 0 | -102 | 8 | 30 |
Quality Earnings: ERAS is currently unprofitable.
Growing Profit Margin: ERAS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ERAS is unprofitable, and losses have increased over the past 5 years at a rate of 30.6% per year.
Accelerating Growth: Unable to compare ERAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ERAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ERAS has a negative Return on Equity (-39.48%), as it is currently unprofitable.